Chronic Inflammatory Demyelinating Polyneuropathy (CIPD) Treatment Aims On Stopping the Immune Attack and Stabilize the Disease
Chronic Inflammatory Demyelinating Polyneuropathy (CIPD) Treatment |
The Chronic
Inflammatory Demyelinating Polyneuropathy Treatment disease develops when
the immune system mistakenly attacks myelin, a protective layer on nerves.
Myelin acts like an insulating coating for electrical wires and protects them
from damage. It is also responsible for transmitting messages between parts of
the body. When myelin is damaged, the electrical impulses travel much slower,
disrupting the flow of messages. CIDP is a disease of the peripheral nervous
system that affects people in the United States. The University of Kansas
Health System is home to one of 30 centers of excellence for the treatment of
CIDP. Peripheral neuropathy is associated with a range of chronic and acute
conditions.
Chronic Inflammatory Demyelinating Polyneuropathy
(CIDP) Treatment is an acquired immune-mediated neuropathy characterized
by progressive weakness in all limbs over a period of about eight weeks. The
clinical presentation of CIDP varies depending on the extent of peripheral
nerve demyelination. It is characterized by progressive weakness and
neurosensory dysfunction. There are several subtypes of the disease, including
atypical and pediatric CIDP.
There are
several treatment options in Chronic
Inflammatory Demyelinating Polyneuropathy Treatment. The first
two include pulse cyclophosphamide (IVIG) and intravenous immunoglobulin
(IVIG). However, patients may also opt for other CIDP treatments. For instance,
patients who experience neuropathic pain may be treated with immunosuppressants
and corticosteroids. A second treatment option is intravenous immunoglobulin
(IVIG), which has been found to improve symptoms in patients with CIDP. The
GBS/CIDP Foundation International has identified clinical centers for diagnosis
and treatment of peripheral nerve disorders. In one study, 47 percent of 59
patients with a diagnosis of CIDP failed to meet the diagnostic criteria. Some
patients were correctly diagnosed with a different neuropathy.
Chronic Inflammatory Demyelinating
Polyneuropathy (CIDP) Treatment is important
at an early stage. The goal of treatment is to stop the immune attack on the
myelin sheath and stabilize the disease. If the disease is severe, multiple
medication trials may be necessary. Throughout the chronic inflammatory
demyelinating polyneuropathy (CIDP), serial clinical examinations will help the
physician determine the optimal regimen.
Patients
with Chronic Inflammatory Demyelinating Polyneuropathy Treatment face
a number of challenges that require proper diagnosis and management. The
outcome measures used in clinical trials should capture impairments in QoL,
disability, and sensory dysfunction. A CIDP disability score is a useful tool
for capturing clinically meaningful changes. CIDP is an acquired autoimmune
disorder of the peripheral nervous system. It causes limb weakness and impaired
sensory function. The immune system destroys the myelin sheath surrounding
peripheral nerves. As a result, CIDP is a life-altering condition that is often
progressive and debilitating.
Comments
Post a Comment